Review
Open access
Sep 2026
Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody–Drug Conjugates
A narrative review of phase II/III trials reporting radiographic progression-free survival (rPFS) or overall survival (OS) in mCRPC, including congress data, to June 2026, graded on a five-level evidence hierarchy to propose a hypothesis-generating four-track framework for discussion between clinicians and patients.
B. Sharaf, M. Al-Rwashdeh, O. El Khatib et al.
· Cancers · 0 citations